949556-46-1

Basic information

• Product Name: 5-(((1-(4-Methoxybenzyl)-1H-pyrazol-5-yl)aMino)Methylene)-2,2-diMethyl-1,3-dioxane-4,6-dione
• Synonyms: 5-(((1-(4-Methoxybenzyl)-1H-pyrazol-5-yl)aMino)Methylene)-2,2-diMethyl-1,3-dioxane-4,6-dione;5-{[2-(4-Methoxy-benzyl)-2H-pyrazol-3-ylamino]-methylene}-2,2-dimethyl-[1,3]dioxane-4,6-dione;1,3-Dioxane-4,6-Dione, 5-[[[1-[(4-Methoxyphenyl)Methyl]-1H-Pyrazol-5-Yl]Amino]Methylene]-2,2-Dimethyl-;1,3-Dioxane-4,6-Dione, 5-[[[1-[(4-Methoxyphenyl)Methyl]-1H-Pyrazol-5-Yl]Amino]Methylene]-2,2-Dimethyl-(WXC04316)
• CAS NO: 949556-46-1
• Molecular Formula: C₁₈H₁₉N₃O₅
• Molecular Weight: 357.36056
• Mol File: 949556-46-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(((1-(4-Methoxybenzyl)-1H-pyrazol-5-yl)aMino)Methylene)-2,2-diMethyl-1,3-dioxane-4,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(((1-(4-Methoxybenzyl)-1H-pyrazol-5-yl)aMino)Methylene)-2,2-diMethyl-1,3-dioxane-4,6-dione(949556-46-1)
• EPA Substance Registry System: 5-(((1-(4-Methoxybenzyl)-1H-pyrazol-5-yl)aMino)Methylene)-2,2-diMethyl-1,3-dioxane-4,6-dione(949556-46-1)

Safety Data

• Hazardous Substances Data: 949556-46-1(Hazardous Substances Data)

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 3528-45-8 1-(4-methoxybenzyl)-1H-pyrazol-5-amine 
• 2033-24-1 cycl-isopropylidene malonate 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 924909-16-0 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol 
• 924909-17-1 4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine 
• 29274-28-0 4-Chloro-1H-pyrazolo<3,4-b>pyridine 
• 1357945-38-0 3-bromo-4-chloro-1H-pyrazolo[3,4-b]pyridine 
• 949558-30-9 4-chloro-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 949558-31-0 4-chloro-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3 ,4-b]pyridine 

Relevant articles and documents

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.